

Faes Farma reaffirms its ambition and strategic plan to 2030 to its shareholders

- The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%.
- All items on the agenda were approved, including the 2024 accounts and the appointment of Beatriz Faro as independent board member, reinforcing the parity and independence of the Board.
- The two recently announced acquisitions, Laboratorios Edol and SIFI, reaffirm the fulfilment of the plan and consolidate the company as a leader in ophthalmology.
- Faes Farma enters the Ibex Medium Cap with the share revalued by 30% so far this year and the market capitalization above 1,400 million euros.

Bilbao, June 25, 2025- Faes Farma held its Ordinary General Shareholders' Meeting today at the Euskalduna Palace on second call, at which all the items on the Agenda were approved by a large majority.

The meeting was attended for the first time by Eduardo Recoder de la Cuadra as the new CEO of Faes Farma, since September 2024, and served to reaffirm to shareholders the commitment to the 2025-2030 Strategic Plan, with which it seeks to be recognized as the best global Spanish pharmaceutical company. This roadmap, already in execution and with tangible results, aims to double both revenues to 1,000 million euros and EBITDA to 240 million euros by 2030, thanks to the organic growth of the pharmaceutical business, supported by M&A operations as a strategic lever for expansion.

"The Meeting has been a new opportunity to reaffirm the direction we have taken as a company. We are in a new stage in which we have redefined our corporate culture with a shared purpose and values that guide each of our decisions, and we have strengthened our organizational structure to be more agile, strategic and global. All of this positions us to ambitiously face the challenges of the sector and move forward with a firm step towards our goal of being a global Spanish pharmaceutical company of reference," said **Eduardo Recoder, CEO of Faes Farma**.

Two strategic operations to boost ophthalmology area

During the first half of the year, two acquisitions have been announced that reinforce the commitment to the new strategic plan: Laboratorios Edol, in Portugal, and SIFI, in Italy, the latter pending approval by the Extraordinary General Meeting of Shareholders to be held on July 16. Both operations are fully aligned with the profile of target companies defined in the plan, framed in a therapeutic area - ophthalmology - with high growth potential due to its high prevalence and the social trends that increase its incidence, and with great capacity for synergies between Faes Farma's current R&D&I capabilities.

Ophthalmology therefore becomes a key therapeutic area for Faes Farma, accounting for around 20% of the total revenues of the Group's combined portfolio. The integration of the two businesses provides a broad and reinforced portfolio with incremental innovation capacity, high potential for internationalization and consolidation in key markets and solid growth results that will strengthen the Group's overall performance thanks to commercial synergies and cross-selling.

Commitment to the shareholder

Today's meeting also approved the annual accounts for 2024, a record year for the company, with 510 million euros in revenues, 129 million euros in EBITDA and a net profit of 111.4 million euros. Growth was mainly driven by the good performance of the pharmaceutical business in Spain, progress in Latin America and the positive evolution of licensing revenues.

In recognition of the good performance of the year, Faes Farma has approved the distribution of a total dividend of 0.179 euros per share, which represents a pay-out close to 51% of the net profit for 2024. This remuneration consists of a cash dividend of 0.041 euros paid in January 2025 and a final cash dividend of 0.138 euros to be paid on July 7, 2025 (last day on which shares with dividend rights are traded, July 2).

The stock market performance has been equally outstanding, with a revaluation of 10% in 2024 and 30% so far in 2025, above the performance of the IBEX, and with a market capitalization that already exceeds 1,400 million euros. In addition, it is worth noting the recent incorporation of Faes Farma to the Ibex Medium Cap, a milestone that reflects the solid work carried out in recent years.

Corporate governance and sustainability

During the Meeting, Faes Farma's commitment to best practices in governance and sustainability was also reinforced. In replacement of Mr. Carlos Alcocer Torra, who has completed his term of office, the appointment of Beatriz Faro Morales as an independent director was approved. In this way, the Board of Directors achieves gender parity, with 50% women, and strengthens its independence profile, also at 50%. In addition, both the Audit and Compliance Committee and the Appointments and Remuneration Committee are made up exclusively of independent directors, reflecting the company's commitment to transparent, balanced and responsible management.

This boost in the composition of the Board is part of one of the pillars of the strategic plan: to generate a positive impact through a corporate culture focused on collective growth, ethics and the creation of sustainable value for all stakeholders. In this sense, Faes Farma has achieved concrete milestones in sustainability in the last year: in 2024 it reached 100% renewable electricity in its operations in Spain and Guatemala, while advancing in the implementation of a Climate Transition Plan and promoting diversity with a workforce that is 54% female, along with new development programs to further expand representation and inclusion. In the long term, the company is working to improve its ESG performance and raise its score in S&P's CSA sustainability index.



About Faes Farma

We are a company with more than 90 years of experience and presence in more than 130 countries through marketed or licensed products. We bring together passion, science and innovation to transform people's health. We research, produce and market prescription drugs, healthcare products and animal nutrition products and we aspire to become a pharmaceutical group that is a benchmark for excellence and cutting edge. At Faes Farma, we are guided by our values to offer the highest quality solutions in health and wellness, with the patient as our priority; to develop innovative products that adapt to the needs of society and to guarantee integrity, transparency and commitment through responsible management and excellence.

Press contact

María Marín
Investor Relations and External Communications Director
mmarin@faes.es
Faes Farma

Cristina López Reques
| 663 371 770 | clopez@harmon.es
Harmon Corporate Affairs